ReviewThe Journal of urology2023
Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer.
Review in The Journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Predictors of self-care in patients with cancer treated with oral anticancer agents: A systematic review.PloS one · 2024Pooled it
- Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.Clinical pharmacokinetics · 2026Observational
- Poor adherence to cancer therapy in Ethiopia: systematic review and meta-analysis.Public health reviews · 2026Review
- Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.Advances in therapy · 2025Article
- Adherence to oral anticancer medications in metastatic versus nonmetastatic breast cancer patients: Insights from a low-middle-income country.Exploratory research in clinical and social pharmacy · 2025Article
- Article
- Evaluation of illness perception and treatment adherence in patients taking oral chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Understanding Treatment Adherence in Chronic Diseases: Challenges, Consequences, and Strategies for Improvement.Journal of clinical medicine · 2025Review
- State of the "Art" in Precision Health Symptom Science Research.Seminars in oncology nursing · 2025Review
- Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer.Advances in therapy · 2025Article
- Pharmacokinetic profile of novel reduced-dose DanzitenCancer chemotherapy and pharmacology · 2025Article
- Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.Future oncology (London, England) · 2025Article
- Real-world pharmacokinetics of trametinib in pediatric low-grade glioma.Cancer chemotherapy and pharmacology · 2025Article
- Optimizing Adherence to Oral Anticancer Agents: Results from an Implementation Mapping Study.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Adverse Drug Reactions and Predictors of Medication Adherence in Patients with Prostate Cancer.The Canadian journal of hospital pharmacy · 2024Article
- Preferences for Tailored Support - Patients' and Health Care Professionals' Experiences Regarding Symptoms and Self-Management Strategies During the First Year After Curatively Intended Prostate Cancer Treatment.Patient preference and adherence · 2024Article
- Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.Research and reports in urology · 2024Article
- Adherence to Hormonal Therapies in Prostate Cancer.Urology practice · 2023Review
- Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this review, we address adherence rates in clinical settings, barriers to compliance with dosing schedules, and potential strategies to overcome challenges in maintaining high levels of adherence. MATERIALS AND
methodsFour studies reporting real-world adherence to prostate cancer medications, 52 studies describing barriers to adherence, and 16 studies on methods to minimize poor adherence were reviewed.
resultsMean nonadherence rates of 25% to 51% have been identified in prostate cancer patients prescribed oral therapies, with higher rates in older patients. An extensive review of prostate cancer patients receiving gonadotropin hormone-releasing hormone agonist injections found an overall nonadherence rate of over 27%. Patients may encounter barriers to complying with dosing instructions related to the medication (eg, complex dosing schedules, the total burden of medication management, fasting or dietary requirements, high medication costs, adverse effects, and drug-drug interactions). Barriers may also be related to patient-specific factors (eg, suboptimal education regarding the importance of adherence, physical limitations and cognitive decline associated with advancing age, living alone without a care partner, high symptom burden, needle phobia, and comorbid mental disorders). Interventions to improve dosing adherence may include automated reminders, treatment diaries, educational materials, and the involvement of patients, family members, care partners, and health care teams.
conclusionsMany oral anticancer medications improve survival in men with prostate cancer, and therefore it is vital to establish good adherence by understanding the pitfalls that patients may encounter. In situations where both oral and injectable drugs are interchangeable, injections of long-acting drugs lead to fewer opportunities for dosing nonadherence than oral therapies. In contrast, oral medicines do not require scheduling for injections and travel for injection appointments. Therefore, maximizing adherence to all treatment regimens will reduce the chance of efficacy failures and likely lead to improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.